Form 4: Intellia Director Muna Bhanji Receives Equity Grant

Director Muna Bhanji acquired 9,200 restricted stock units and 13,300 stock options in Intellia Therapeutics.

Summary

• Director Muna Bhanji was granted 9,200 restricted stock units (RSUs) on June 9, 2026.
• Director Muna Bhanji was granted 13,300 stock options with an exercise price of $12.89 on June 9, 2026.
• The stock options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.
• Following these transactions, the reporting person holds 36,403 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.
• The grant indicates continued commitment from a board member.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the value of the granted options.
• Vesting conditions are tied to future service and meeting dates.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies focused on gene editing technologies.

Comparison to Industry Standards

• The grant structure is consistent with standard director compensation packages for mid-cap biotechnology firms.
• Vesting schedules align with typical annual meeting cycles observed in the industry.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the stock options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Equity Compensation, Director Compensation